Jan Geissler - Chronic Myeloid Leukemia - CML
''Being a leukemia survivor that had participated in clinical trials to survive, Jan founded the online patient community Leukämie-Online/LeukaNET (http://www.leukaemie-online.de) in 2002, which is one of the most frequented online platforms for leukemia patients in the German speaking Internet today. In 2003, he co-founded the European Cancer Patient Coalition (European umbrella association of 315 cancer patient groups, http://www.ecpc-online.org ) and became its first full time director 2008. In 2007, Jan also co-founded the CML Advocates Network (http://www.cmladvocates.net), which is now connecting 53 leukaemia patient groups from all continents. He today speaks for patients in various steering committees and advisory boards. He acts as an independent EU expert reviewing FP7 projects. In his professional life, he held various managerial positions in think tanks of the telecommunications and media industry before he focused his work on patient advocacy in 2008. Today he is founder and managing director of Patvocates, acting as independent consultant in cancer policy, patient advocacy and social media''
Extract of http://www.rarediseaseblogs.net/author/jangeissler/
Extract of http://www.rarediseaseblogs.net/author/jangeissler/
VIDEOS
Interview with Jan Geissler
November 21, 2017, WithTheEconomist
Treatment-free remission (TFR) – the safety of stopping treatment in chronic myeloid leukemia (CML)
November 2, 2017, cmladvocates
Patient involvement at ASH 2016 and beyond
February 28, 2017, VJHemOnc – Video Journal of Hematological Oncology
Generics for chronic myeloid leukemia treatment – a hot topic at ASH 2016 as imatinib patent expires
February 24, 2017, VJHemOnc – Video Journal of Hematological Oncology
ABL001 – a new BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment
February 24, 2017, VJHemOnc – Video Journal of Hematological Oncology
The Latest in CML, A Global Patient-Advocate's Perspective with Jan Geissler
January 24, 2016, Patient Power
Patient Advocate Perspective: Choosing to Stop CML Treatment After Remission
January 22, 2015, Patient Power
Jan Geissler Explains Differing Perceptions for Living With CML
December 8, 2014, AJMCtv
Why Patients Should Become Research Advocates
June 26, 2013, Patient Power
Changing the paradigm in frontline CML therapy
Prof Giuseppe Saglio - University of Turin, Italy;
Dr Delphine Rea - Saint Louis Hospital, Paris;
Jan Geissler - Co-Founder, CML Advocates Network
February 21, 2011, ecancer.tv
ARTICLES
Jan Geißler: We, the patients
January 16, 2010,Cancerworld
Jan Geissler on Facebook Jan Geissler on Twitter
Interview with Jan Geissler
November 21, 2017, WithTheEconomist
Treatment-free remission (TFR) – the safety of stopping treatment in chronic myeloid leukemia (CML)
November 2, 2017, cmladvocates
Patient involvement at ASH 2016 and beyond
February 28, 2017, VJHemOnc – Video Journal of Hematological Oncology
Generics for chronic myeloid leukemia treatment – a hot topic at ASH 2016 as imatinib patent expires
February 24, 2017, VJHemOnc – Video Journal of Hematological Oncology
ABL001 – a new BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment
February 24, 2017, VJHemOnc – Video Journal of Hematological Oncology
The Latest in CML, A Global Patient-Advocate's Perspective with Jan Geissler
January 24, 2016, Patient Power
Patient Advocate Perspective: Choosing to Stop CML Treatment After Remission
January 22, 2015, Patient Power
Jan Geissler Explains Differing Perceptions for Living With CML
December 8, 2014, AJMCtv
Why Patients Should Become Research Advocates
June 26, 2013, Patient Power
Changing the paradigm in frontline CML therapy
Prof Giuseppe Saglio - University of Turin, Italy;
Dr Delphine Rea - Saint Louis Hospital, Paris;
Jan Geissler - Co-Founder, CML Advocates Network
February 21, 2011, ecancer.tv
ARTICLES
Jan Geißler: We, the patients
January 16, 2010,Cancerworld
Jan Geissler on Facebook Jan Geissler on Twitter
